Perceptive Advisors Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VRNA
Verona Pharma
VRNA
|
+$95.5M |
| 2 |
Viking Therapeutics
VKTX
|
+$57.4M |
| 3 |
argenx
ARGX
|
+$52.2M |
| 4 |
Adagio Medical Holdings
ADGM
|
+$46.7M |
| 5 |
Oruka Therapeutics
ORKA
|
+$43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$441M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$74.1M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$60M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$38.8M |
| 5 |
SpringWorks Therapeutics
SWTX
|
+$35.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.6% |
| 2 | Miscellaneous | 1.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| – | – |
-1,261,710
| Closed | -$833K | – |
|
|
127
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| – | – |
-10,794,876
| Closed | -$441M | – |
|
Similar funds
Perceptive Advisors's Q3 2024 Portfolio in Review
As of Q3 2024, Perceptive Advisors held 127 positions worth $4.73B, up 14% from $4.15B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Perceptive Advisors withdrew a net $244M in Q3 2024, closing 19 positions and reducing 25 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $441M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Perceptive Advisors opened a new position in Adagio Medical Holdings worth $25.3M.
- Perceptive Advisors's largest Q3 2024 buy was Adagio Medical Holdings: 9,812,419 shares worth $25.3M.
- Perceptive Advisors added most to Verona Pharma in Q3 2024, an estimated $95.5M increase.
- Perceptive Advisors's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $60M.
- Perceptive Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $441M.
- Perceptive Advisors's ten largest holdings make up 46% of its $4.73B portfolio in Q3 2024.
- Perceptive Advisors opened 17 new positions and closed 19 in Q3 2024.
- Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $4.73B.
Based on Perceptive Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.